Cipla Shares Surge 4% as Citi Identifies Key 90-Day Growth Catalysts

Pharmaceutical giant Cipla saw its shares rally by 4% to a high of Rs 1,409 on the BSE following a bullish update from Citi. The international brokerage has placed the stock on a "90-day Positive Catalyst Watch," maintaining a 'Buy' rating with a target price of Rs 1,700, implying a potential upside of over 25%.

Near-Term Triggers in the US Market

Citi’s optimism is heavily anchored in several upcoming regulatory and product milestones in the United States. A primary driver is the anticipated approval of gFlovent from Cipla's Goa facility, a move expected to significantly bolster the company's US market presence. Additionally, the expected launch of gVentolin is viewed as a strategic growth lever.

The brokerage also highlighted Cipla's strong competitive positioning in the US, noting that its Nintedanib product has already captured nearly 50% of the market share. After a period of recent weakness, Cipla's US business is now positioned for a substantial revenue rebound. Furthermore, a pending re-inspection of the Indore plant by the USFDA presents a potential upside; a favorable outcome could act as a powerful catalyst for investor sentiment.

Robust Domestic Performance and Margin Stability

While the US market offers high-growth potential, Cipla’s domestic operations remain a cornerstone of its stability. The India business, which contributes approximately two-thirds of the company's EBITDA, continues to perform strongly, supported by a recovery in its respiratory portfolio.

Investors are also finding comfort in the macroeconomic landscape. Citi noted that easing geopolitical tensions have helped alleviate concerns regarding raw material costs, which should assist in stabilizing margins. The brokerage suggests that Cipla's earnings have likely bottomed out following the impact of gRevlimid, setting the stage for a recovery phase.

Valuation Advantage Over Domestic Peers

One of the most compelling arguments presented by Citi is Cipla's attractive valuation compared to other India-focused pharmaceutical players. Despite its strong market position, Cipla offers more reasonable entry points for investors.

Specifically, the brokerage pointed out that Cipla's India business is valued at 7.8 times FY26 sales, which is more conservative than Mankind Pharma, which trades at 8.5 times. Currently, the stock trades at 25x FY27E earnings and 21x FY28E earnings, presenting a favorable risk-reward profile for long-term investors looking for exposure to the Indian healthcare sector.

Recent Financial Performance Context

The bullish outlook comes despite a challenging Q4 performance. Cipla reported a 55% year-on-year decline in consolidated net profit, falling to Rs 555 crore from Rs 1,222 crore in the same quarter last year. Revenue from operations also saw a slight dip of 3% to Rs 6,541 crore. For the full financial year ending March 31, 2026, the company reported a 2% rise in total revenue to Rs 28,163 crore, even as net profit declined by 26% YoY.

Key Takeaways

  • Bullish Target: Citi maintains a 'Buy' rating on Cipla with a target price of Rs 1,700, citing a 25.55% upside potential.
  • US Growth Drivers: Key catalysts include the potential approval of gFlovent, the launch of gVentolin, and a successful USFDA re-inspection of the Indore plant.
  • Attractive Valuation: Cipla offers a more reasonable valuation for its India business (7.8x FY26 sales) compared to domestic peers like Mankind (8.5x).